Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Vegetable Oil Ingredient Key to Destroying Gastric Disease Bacteria

November 25, 2014 – 10:03 am | Edit Post

The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils.

Vegetable Oil Ingredient Key to Destroying Gastric Disease Bacteria

November 25, 2014 – 10:03 am | Edit Post

The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils.

Ebola Patient Who Received Aethlon Medical Hemopurifier Therapy Has Been Discharged From Hospital

November 24, 2014 – 5:00 pm | Edit Post

Ebola Patient Who Received Aethlon Hemopurifier Therapy Has Been Discharged From HospitalSAN DIEGO, Nov. 25, 2014 /PRNewswire/ –Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed…

University of California, San Francisco (UCSF) And OncoSec Medical Inc. Collaborate To Evaluate Investigational Combination Of ImmunoPulse And Anti-PD-1 Treatment

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, and OncoSecs ImmunoPulse (intratumoral IL-12) in…

Receptos Announces Full Exercise Of Underwriters’ Option To Purchase Additional Shares And Completion Of Underwritten Public Offering Of Common Stock

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 24, 2014 (GLOBE NEWSWIRE) — Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the completion of the previously announced underwritten public offering of an aggregate of 4…

Arena Pharmaceuticals, Inc. Issued Composition Of Matter Patent By United States Patent And Trademark Office For Ralinepag And Related Compounds

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 25, 2014 /PRNewswire/ –Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S. Patent No. 8,895,776, entitled “Modulators of the Prostacyclin (PGI2) Receptor Useful for the Treatment of Disorders Related Thereto,” covering ralinepag…

ACADIA Pharmaceuticals, Inc. To Present At Upcoming Investor Conferences

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:•The Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 20…

Volcano Corporation Presentation At Piper Jaffray Conference To Be Webcast

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 25, 2014 /PRNewswire/ — Volcano Corporation (Nasdaq: VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary and peripheral visualization, physiology diagnostics and therapies, said today…

Sequenom Inc. Announces Participation At The 26th Annual Piper Jaffray Healthcare Conference

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 25, 2014 /PRNewswire/ –Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company’s participation at the 2014 Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York, NY

Isis Pharmaceuticals, Inc. Initiates Phase 3 Study Of ISIS-SMN Rx In Children With Spinal Muscular Atrophy

November 24, 2014 – 5:00 pm | Edit Post

CARLSBAD, Calif., Nov. 25, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA). SMA is a severe and rare genetic neuromuscular disease…